Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GoodRx HoldingsGDRX -2.22%65 5-Year Yield-on-Cost % is 0.00 as of Jul. 23, 2026. GuruFocus rates GDRX with a GF Score™ of 65/100 and a GF Value™ of $5.66 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 277 Healthcare Providers & Services companies, GoodRx Holdings ranks worse than 361010.47% on this metric.
GoodRx Holdings's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for GoodRx Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:
GDRX's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.9 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
GoodRx Holdings 5-Year Yield-on-Cost % Related Terms
GDRX vs CERT, TALK, HSTM: 5-Year Yield-on-Cost % Comparison
For the Health Information Services subindustry, GoodRx Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GoodRx Holdings 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, GoodRx Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where GoodRx Holdings's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of GoodRx Holdings is calculated as
GoodRx Holdings (GDRX) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on GoodRx Holdings and its competitors. According to the industry distribution chart, GoodRx Holdings ranks #999999 out of 277 companies in the Healthcare Providers & Services industry.
Is GoodRx Holdings' 5-Year Yield-on-Cost % too high?
GoodRx Holdings' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, GoodRx Holdings ranks #999999 out of 277 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, GoodRx Holdings has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does GoodRx Holdings' 5-Year Yield-on-Cost % compare to CERT and TALK?
According to the Healthcare Providers & Services industry distribution chart, GoodRx Holdings ranks #999999 out of 277 companies for 5-Year Yield-on-Cost %. This places GoodRx Holdings in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.90, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on GoodRx Holdings and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GoodRx Holdings's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GoodRx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GoodRx Holdings (GDRX) is currently considered Possible Value Trap. The stock's GF Value™ is $5.66, compared to a current price of $2.87 — trading 49.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. GoodRx Holdings' overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For GoodRx Holdings (GDRX), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GoodRx Holdings (GDRX) Overvalued in 2026?
Based on GuruFocus' analysis, GoodRx Holdings stock appears to be undervalued.
The current stock price of $2.87 is trading 49.4% below its estimated GF Value™ of $5.66.
GuruFocus considers GoodRx Holdings to be Possible Value Trap.
Key valuation signals for GDRX:
5-Year Yield-on-Cost %: 0.00
GF Value™: $5.66 vs. price of $2.87 (49.4% below fair value)
No single metric tells the full story. See the GDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
65GF Score
Get the complete analysis for GDRX
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GDRX has been successfully added to your 
